- Home
- EVMN vs AMPH Comparison
EVMN vs AMPH Comparison
Compare EVMN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | AMPH |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 869.1M | 971.8M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | EVMN | AMPH |
|---|---|---|
| Price | $13.32 | $20.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $43.88 | $28.38 |
| AVG Volume (30 Days) | ★ 1.0M | 624.0K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | N/A | $4.64 |
| P/E Ratio | ★ N/A | $147.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.89 | $16.65 |
| 52 Week High | $33.20 | $31.26 |
Technical Indicators
Market Signals| Indicator | EVMN | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 50.65 |
| Support Level | N/A | $18.57 |
| Resistance Level | $20.37 | $20.13 |
| Average True Range (ATR) | 1.74 | 0.95 |
| MACD | -0.52 | 0.15 |
| Stochastic Oscillator | 0.59 | 46.56 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.